ERBB2 and ovarian cancer: Continuous 7-day treatment (20 MBq/mL+0.031μg/mL T-DM1) disrupted 3D tumor spheroids, suggesting potential for HER2-positive breast/ovarian cancer treatment despite preferential suitability of inorganic nanoradiopharmaceuticals for localized delivery (Figure 10) (149).